Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Effect of Lidocaine on Adductor Canal Block Duration
NCT02172729Phase 4
Key facts
- Status
- Completed
- Start
- Jun 2014
- Primary completion
- Jul 2014
- Countries
- 1
- Sponsor
- Rigshospitalet
- Modality
- Small Molecules
- Drugs
- lidocaine
01
Overview
Phase 4 trial of lidocaine (2 arms), sponsored by Rigshospitalet. Primary endpoint: Duration of sensory block assessed with pinprick. Started Jun 2014; status: completed.
02
Design
2 armsACB with lidocaine 5 mg/ml
Adductor canal block with 20 ml lidocaine 5 mg/ml, single bolus
ACB with lidocaine 15 mg/ml
Adductor canal block with 20 ml lidocaine 15 mg/ml, single bolus
03
Who it enrols
Healthy volunteers (ASA 1) with BMI 18-25, excluding those with diabetes, prior lower limb trauma/surgery, or allergy to study medication.
04
Endpoints
Primary
Duration of sensory block assessed with pinprick
Secondary
Duration of sensory block assessed by heat pain detection threshold
Duration of sensory block assessed by warmth detection threshold
Duration of sensory block assessed by pain during 1 minute of warmth stimulation
Duration of sensory block assessed by tolerance to transcutaneal electrical stimulation
Duration of sensory block assessed by cold sensation with an alcohol swab
Duration of motor block assessed as maximum voluntary isometric contraction
Time to onset of sensory block assessed by pinprick
Beyond the preview
Go deeper on NCT02172729.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172729.